Health tech company Aetion and the U.S. Food and Drug Administration signed a collaboration agreement to use real-world data to advance the understanding of and response to COVID-19.

The U.S. Food and Drug Administration gave the green light to Sanofi’s Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor.

Shares of Karyopharm Therapeutics soared after the company posted positive Phase III results in multiple myeloma and announced plans for a regulatory submission in the second quarter of 2020 for a combination of Xpovio, Velcade and Dexamethasone.

Parexel will tap into real-world data to connect the biopharmaceutical services provider to data from the company’s clinical trials through a multi-year partnership with Bay Area-based Datavant.

Syapse, which accelerates precision medicine through insights derived from the company’s global health system network, announced a strategic collaboration with Pfizer Inc. to advance cancer outcomes research using real-world evidence toward the ultimate goal of improving patient health.

Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.

A recent report written by SVB Leerink analysts that looked at eight companies and their research-and-development portfolios found that in the past five years, they progressed only 24 percent of their new molecular entities to approval.

In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated the company’s emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.

Eisai Co. Ltd. initiated Phase 3 clinical trials of the Alzheimer’s treatment BAN2401 one day after the Japanese drugmaker and U.S. partner Biogen Inc. scrapped studies for the Alzheimer’s drug aducanumab.

Roche’s Flatiron Health and the U.S. Food and Drug Administration’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement.